Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects

Diabetology & Metabolic Syndrome

Mahmoud Djalali³  Mohammad Reza Eshraghian²  Saeed Hosseini⁴  Ali Akbar Saboor-Yaraghi³  Fariba Koohdani³  Seyed Ali Keshavarz⁴  Arash Hossein-nezhad¹  Khadijeh Mirzaei³ 

[1] Department of Medicine, Section of Endocrinology, Nutrition, and Diabetes, Vitamin D, Skin and Bone Research Laboratory, Boston University Medical Center, Boston, Massachusetts, United States of America;Department of Biostatistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran;Cellular and Molecular Nutrition Department, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran;Clinical Nutrition Department, School of Nutritional Science and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

关键词: Obesity;    Adipokines;    Circulating PPARγ;    Metabolic syndrome;   

Others  :  812337
DOI  :  10.1186/1758-5996-5-79

 received in 2013-08-09, accepted in 2013-12-06,  发布年份 2013

【 摘 要 】

Background

Peroxisome proliferator-activated receptor gamma (PPARγ) has direct and indirect function in adipokines production process. We aimed to assess the possible influence of circulating PPARγ on relative risk of metabolic syndrome and also examine the association between circulating PPARγ and adipokines levels among obese subjects.

Methods

A total of 96 obese subjects (body mass index (BMI) ≥30) were included in the current cross-sectional study. We assessed the body composition with the use of Body Composition Analyzer BC-418MA - Tanita. The MetS (metabolic syndrome) was defined based on the National Cholesterol Education Program Adult Treatment Panel III. All baseline blood samples were obtained following an overnight fasting. Serum concentrations of adipokines including Retinol binding protein 4 (RBP4), omentin-1, vaspin, progranulin, nesfatin-1 and circulating PPARγ was measured with the use of an enzyme-linked immunosorbent assay method. Statistical analyses were performed using software package used for statistical analysis (SPSS).

Results

We found main association between circulating PPARγ and body composition in obese population. The risk of metabolic syndrome in subjects with higher concentration of PPARγ was 1.9 fold in compared with lower concentration of PPARγ after adjustment for age, sex and BMI. There was significant association between PPARγ and adipokines, specially nesfatin-1 and progranulin. Defined adipokines pattern among participants demonstrated the markedly higher concentration of vaspin, RBP4 and nesfatin-1 in participants with MetS compared to non-MetS subjects.

Conclusions

It appears all of studied adipokines might have association with PPARγ level and might simultaneously be involve in some common pathway to make susceptible obese subjects for MetS.

【 授权许可】

   
2013 Mirzaei et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN: Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Diabetes Care 2005, 28:391-397.
• [2]Wada J: Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17:327-333.
• [3]Wang Q, Yin J, Xu L, Cheng H, Zhao X, Xiang H, Lam HS, Mi J, Li M: Prevalence of metabolic syndrome in a cohort of Chinese schoolchildren: comparison of two definitions and assessment of adipokines as components by factor analysis. BMC Public Health 2013, 13:1471-2458.
• [4]Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
• [5]Nakata M, Yada T: Role of NUBC2/nesfatin-1 in glucose control: diverse functions in islets adipocytes and brain. Curr Pharm Des 2013, 25:25.
• [6]Wang P, Menheere PP, Astrup A, Andersen MR, Baak MA, Larsen TM, Jebb S, Kafatos A, Pfeiffer AF, Martinez JA, et al.: Metabolic syndrome, circulating RBP4, testosterone, and SHBG predict weight regain at 6 months after weight loss in men. Obesity 2013, 14:20311.
• [7]Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA: Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013, 98:2012-3673.
• [8]Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS: Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol 2011, 75:628-635.
• [9]Richter J, Focke D, Ebert T, Kovacs P, Bachmann A, Lossner U, Kralisch S, Kratzsch J, Beige J, Anders M, et al.: Serum levels of the adipokine progranulin depend on renal function. Diabetes Care 2013, 36:410-414.
• [10]Trayhurn P, Bing C, Wood IS: Adipose tissue and adipokines–energy regulation from the human perspective. J Nutr 2006, 136:1935S-1939S.
• [11]Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama 2001, 285:2486-2497.
• [12]Skurk T, Alberti-Huber C, Herder C, Hauner H: Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007, 92:1023-1033.
• [13]Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM: PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4:611-617.
• [14]Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 1998, 101:1354-1361.
• [15]Waki H, Yamauchi T, Kadowaki T: Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma. Nihon Rinsho 2010, 68:210-216.
• [16]Sale MM, Rich SS: Genetic contributions to type 2 diabetes: recent insights. Expert Rev Mol Diagn 2007, 7:207-217.
• [17]Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR: Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 2007, 15:1258-1271.
• [18]Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A: Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Am J Hypertens 2007, 20:206-210.
• [19]Ricote M, Li A, Willson T, Kelly C, Glass C: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
• [20]Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka T: Proinflammatory stimulation and pioglitazone treatment regulate PPARγ levels in PBMCs from healthy controls and multiple sclerosis patients. J Immunol 2005, 175:4948-4955.
• [21]Macias-Gonzalez M, Cardona F, Queipo-Ortuño M, Bernal R, Martin M, Tinahones F: PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. J Nutr Biochem 2008, 138:903-907.
• [22]Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, Farrar WL: Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000, 275:4541-4544.
• [23]Spiegelman BM: PPARgamma in monocytes: less pain, any gain? Cell 1998, 93:153-155.
• [24]Rosen ED, Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734.
• [25]McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD: Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003, 100:131-136.
• [26]Shi H, Yu X, Li Q, Ye X, Gao Y, Ma J, Cheng J, Lu Y, Du W, Du J, et al.: Association between PPAR-gamma and RXR-alpha gene polymorphism and metabolic syndrome risk: a case–control study of a Chinese Han population. Arch Med Res 2012, 43:233-242.
• [27]Robitaille J, Despres JP, Perusse L, Vohl MC: The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the quebec family study. Clin Genet 2003, 63:109-116.
• [28]Mousavinasab F, Tahtinen T, Jokelainen J, Koskela P, Vanhala M, Oikarinen J, Laakso M, Keinanen-Kiukaanniemi S: The Pro12Ala polymorphism of the PPAR gamma 2 gene influences sex hormone-binding globulin level and its relationship to the development of the metabolic syndrome in young Finnish men. Endocrine 2006, 30:185-190.
• [29]Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R: Homeostasis model assessment: insulin resistance and _cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [30]Mirzaei K, Hossein-Nezhad A, Chamari M, Shahbazi S: Evidence of a role of ANGPTL6 in resting metabolic rate and its potential application in treatment of obesity. Minerva Endocrinol 2011, 36:13-21.
• [31]Miles PD, Barak Y, Evans RM, Olefsky JM: Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am J Physiol Endocrinol Metab 2003, 284:E618-626.
• [32]Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, et al.: PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
• [33]Kadowaki T: PPAR gamma agonist and antagonist. Nihon Yakurigaku Zasshi 2001, 118:321-326.
• [34]Miles PD, Barak Y, He W, Evans RM, Olefsky JM: Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000, 105:287-292.
• [35]Lteif AA, Han K, Mather KJ: Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005, 112:32-38.
• [36]Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali M, Asgari F: Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab 2010, 7:1743-7075.
• [37]Wallace TM, Levy JC, Matthews DR: Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
• [38]Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G: Comparative evaluation of simple indices of insulin resistance. Metabolism 2004, 53:1522-1526.
• [39]Defronzo RA: Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes 1979, 28:1095-1101.
• [40]Slattery MJ, Bredella MA, Thakur H, Torriani M, Misra M: Insulin Resistance and Impaired Mitochondrial Function in Obese Adolescent Girls. Metab Syndr Relat Disord 2013, 19:19.
• [41]Reaven GM, Hollenbeck CB, Chen YD: Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia 1989, 32:52-55.
• [42]Lehrke M, Lazar M: The many faces of PPARγ. Cell 2005, 123:993-999.
• [43]Straus D, Pascual G, Li M, Welch J, Ricote M, Hsiang C, Sengchanthalangsy L: 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000, 97:4844-4849.
• [44]Saldanha JF, Carrero JJ, Lobo JC, Stockler-Pinto MB, Leal VO, Calixto A, Geloneze B, Mafra D: The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Regul Pept 2012, 173:82-85.
• [45]Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S: Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. J Endocrinol 2011, 208:R9-R16.
• [46]Yamada M, Horiguchi K, Umezawa R, Hashimoto K, Satoh T, Ozawa A, Shibusawa N, Monden T, Okada S, Shimizu H, Mori M: Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology 2010, 151:2494-2503.
• [47]Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X: Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007, 92:4827-4834.
• [48]Rosell M, Hondares E, Iwamoto S, Gonzalez FJ, Wabitsch M, Staels B, Olmos Y, Monsalve M, Giralt M, Iglesias R, Villarroya F: Peroxisome proliferator-activated receptors-alpha and -gamma, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. Endocrinology 2012, 153:1162-1173.
• [49]de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
• [50]Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M: Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Regul Pept 2013, 182:1-6.
• [51]Bluher M: Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012, 41:176-182.